News

Releases

19. June, 2025

Strengthening Executive Management with the promotion of Martin Juhl

On 19 June – Cessatech A/S (“Cessatech” or “the Company”) and the Board of...

Read more

Releases

28. May, 2025

Positive top-line results from its final CT001 Study 0202

On 28 May – Cessatech A/S (“Cessatech” or “the Company”) announces top-line results from...

Read more

Releases

28. February, 2025

Annual Report 2024

Today, Friday 28. February, Cessatech has released the Annual Report for 20024. We have...

Read more

Releases

4. February, 2025

Positive Notified Body opinion under MDR for CT001

On 4 February – Cessatech A/S (“Cessatech” or “the Company”) announces that the Company...

Read more

Media

29. October, 2024

Company presentation Nordnet – follow up

In case you did not have time to watch the online Nordnet company presentation,...

Read more

Releases

16. October, 2024

Halfway milestone patient recruitment in Paediatric Study 0202

Cessatech announces that recruitment has today reached the halfway point for patient recruitment with...

Read more

Releases

26. August, 2024

Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001

Cessatech and Proveca enter an exclusive agreement for the commercialization of CT001 world-wide excluding...

Read more

Releases

12. August, 2024

Cessatech extends Loan Facility Agreement to DKK 10 million…

Cessatech extends its undrawn Loan Facility Agreement to DKK 10 million to support the...

Read more

Releases

5. July, 2024

Anders Dyhr Dombernowsky-Toft appointed to the Board of Directors

Cessatech has today appointed Anders Dyhr Dombernowsky-Toft to the Board of Directors at the...

Read more

Releases

28. June, 2024

New data on paediatric pain relief at the PAGE conference in Rome favouring its lead candidate CT001

On 28 June – Cessatech A/S (“Cessatech” or “the Company”) announces that the presentation...

Read more

Releases

3. June, 2024

Cessatech announces superior simulated pain efficacy in children

Cessatech announces the final simulated efficacy data in children with CT001 from the abstract...

Read more

Releases

27. May, 2024

Cessatech reports first patient dosed in final Safety Study 0202 of lead product candidate CT001

Cessatech A/S announces that the Safety Study 0202 has now been initiated with dosing...

Read more

Stay up to date!

Subscribe and get notified on Cessatech's latest news.
An acceptance email will be sent to you, please check your spam.